Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $44.1 million.

  • Celldex Therapeutics' Non-Current Assets fell 53.45% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.0 million, marking a year-over-year increase of 2310.31%. This contributed to the annual value of $45.2 million for FY2024, which is 3314.37% up from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Non-Current Assets is $44.1 million, which was down 53.45% from $44.0 million recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Non-Current Assets high stood at $45.7 million for Q1 2025, and its period low was $33.3 million during Q1 2022.
  • Its 5-year average for Non-Current Assets is $37.3 million, with a median of $34.9 million in 2023.
  • Per our database at Business Quant, Celldex Therapeutics' Non-Current Assets tumbled by 3633.08% in 2021 and then skyrocketed by 3636.61% in 2025.
  • Celldex Therapeutics' Non-Current Assets (Quarter) stood at $33.8 million in 2021, then increased by 3.63% to $35.0 million in 2022, then dropped by 3.16% to $33.9 million in 2023, then skyrocketed by 33.14% to $45.2 million in 2024, then fell by 2.39% to $44.1 million in 2025.
  • Its Non-Current Assets was $44.1 million in Q3 2025, compared to $44.0 million in Q2 2025 and $45.7 million in Q1 2025.